Beneficial activity of Enterococcus faecalis CECT 7121 in the anti-lymphoma protective response.

CASTRO, MARISA; MOLINA, MATÍAS; DI SCIULLO, MARÍA PAULA; AZPIROZ MARÍA; LEOCATA NIETO, FRANCISCO; STERÍN-SPEZIALE, NORMA; MONGINI, CLAUDIA; MANGHI, MARCELA

JOURNAL OF APPLIED MICROBIOLOGY

WILEY-BLACKWELL PUBLISHING, INC

Año: 2010 vol. 109 p. 1234 - 1243

1364-5072

To study the anti-tumour effects of Enterococcus faecalis CECT7121 on LBC cells, an aggressive murine T-cell lymphoma that kills the host in 18 days when is intraperitoneally (ip) administrated. Methods and Results: studies have shown that LBC cell proliferation was inhibited by Ent. faecalis CECT7121 stimulus in a dose dependent manner, inducing apoptosis. The production of ceramide was involved in the latter effect. In order to undertake in vivo studies, syngeneic BALB/c mice pre-treated ip with Ent. faecalis CECT7121 (2.5x108 CFU) were challenged ip with LBC cells (1.0x108 the day after. On day 30 post-inoculation of LBC cells, 70% of Ent. faecalis CECT7121 pre-treated mice survived, whereas no survivals were recorded in the control group. A group of surviving mice was re-challenged with LBC cells and 89% of them survived. Upon stimulation with irradiated LBC cells, spleen cell proliferation, high IFN-gamma, IL-12 and IL-10 levels were observed in surviving animals. Conclusions: Ent. faecalis CECT7121 affected multiple factors of the tumour establishment by: down-regulating the LBC cell proliferation, and inducing apoptosis in these cells; and enhancing the immune response which protects animals from lymphoma challenge and rechallenge. Significance and Impact of the Study: This study demonstrate that Ent. Faecalis CECT7121 has potential as a probiotic that could facilitate the development of novel complements to therapeutic strategies against oncological diseases.